Cargando…
A pilot study on the impact of known drug-drug interactions in cancer patients
BACKGROUND: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547416/ https://www.ncbi.nlm.nih.gov/pubmed/26303220 http://dx.doi.org/10.1186/s13046-015-0201-2 |
_version_ | 1782387068926689280 |
---|---|
author | Ussai, Silvia Petelin, Riccardo Giordano, Antonio Malinconico, Mario Cirillo, Donatella Pentimalli, Francesca |
author_facet | Ussai, Silvia Petelin, Riccardo Giordano, Antonio Malinconico, Mario Cirillo, Donatella Pentimalli, Francesca |
author_sort | Ussai, Silvia |
collection | PubMed |
description | BACKGROUND: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medications. Moreover, most cancer patients are elderly and require additional medications for comorbidities. Aim of this preliminary observational study was to evaluate the incidence of well known and established DDIs in a cohort of cancer outpatients undergoing multiple treatments. METHODS: Anamnestic and clinical data were collected for 64 adult patients in the ambulatory setting with malignant solid tumors who were receiving systemic anticancer treatment. Patients also declared all drugs prescribed by other specialists or self-taken in the previous 2 weeks. DDIs were divided into two different groups: ‘neoplastic DDIs’ (NDDIs), involving antitumoral drugs, and ‘not neoplastic DDIs’ (nDDIs), involving all other classes of drugs. The severity of DDIs was classified as major, moderate and minor, according to the ‘Institute for Pharmacological Research Mario Negri’ definition. RESULTS: About 34 % of cancer outpatients within our cohort were prescribed/assumed interacting drug combinations. The most frequent major NDDIs involved the anticoagulant warfarin (33 % of total NDDIs) that, in association with tamoxifen, or capecitabine and paclitaxel, increased the risk of haemorrhage. About 60 % of nDDIs involved acetylsalicylic acid. CONCLUSIONS: Overall, 16 % of DDIs were related to an A-level strength of recommendation to be avoided. The lack of effective communication among specialists and patients might have a role in determining therapeutic errors. Our pilot study, although limited by a small cohort size, highlights the urgent need of implementing the clinical management of cancer outpatients with new strategies to prevent or minimize potential harmful DDIs. |
format | Online Article Text |
id | pubmed-4547416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45474162015-08-25 A pilot study on the impact of known drug-drug interactions in cancer patients Ussai, Silvia Petelin, Riccardo Giordano, Antonio Malinconico, Mario Cirillo, Donatella Pentimalli, Francesca J Exp Clin Cancer Res Research BACKGROUND: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medications. Moreover, most cancer patients are elderly and require additional medications for comorbidities. Aim of this preliminary observational study was to evaluate the incidence of well known and established DDIs in a cohort of cancer outpatients undergoing multiple treatments. METHODS: Anamnestic and clinical data were collected for 64 adult patients in the ambulatory setting with malignant solid tumors who were receiving systemic anticancer treatment. Patients also declared all drugs prescribed by other specialists or self-taken in the previous 2 weeks. DDIs were divided into two different groups: ‘neoplastic DDIs’ (NDDIs), involving antitumoral drugs, and ‘not neoplastic DDIs’ (nDDIs), involving all other classes of drugs. The severity of DDIs was classified as major, moderate and minor, according to the ‘Institute for Pharmacological Research Mario Negri’ definition. RESULTS: About 34 % of cancer outpatients within our cohort were prescribed/assumed interacting drug combinations. The most frequent major NDDIs involved the anticoagulant warfarin (33 % of total NDDIs) that, in association with tamoxifen, or capecitabine and paclitaxel, increased the risk of haemorrhage. About 60 % of nDDIs involved acetylsalicylic acid. CONCLUSIONS: Overall, 16 % of DDIs were related to an A-level strength of recommendation to be avoided. The lack of effective communication among specialists and patients might have a role in determining therapeutic errors. Our pilot study, although limited by a small cohort size, highlights the urgent need of implementing the clinical management of cancer outpatients with new strategies to prevent or minimize potential harmful DDIs. BioMed Central 2015-08-25 /pmc/articles/PMC4547416/ /pubmed/26303220 http://dx.doi.org/10.1186/s13046-015-0201-2 Text en © Ussai et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Ussai, Silvia Petelin, Riccardo Giordano, Antonio Malinconico, Mario Cirillo, Donatella Pentimalli, Francesca A pilot study on the impact of known drug-drug interactions in cancer patients |
title | A pilot study on the impact of known drug-drug interactions in cancer patients |
title_full | A pilot study on the impact of known drug-drug interactions in cancer patients |
title_fullStr | A pilot study on the impact of known drug-drug interactions in cancer patients |
title_full_unstemmed | A pilot study on the impact of known drug-drug interactions in cancer patients |
title_short | A pilot study on the impact of known drug-drug interactions in cancer patients |
title_sort | pilot study on the impact of known drug-drug interactions in cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547416/ https://www.ncbi.nlm.nih.gov/pubmed/26303220 http://dx.doi.org/10.1186/s13046-015-0201-2 |
work_keys_str_mv | AT ussaisilvia apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT petelinriccardo apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT giordanoantonio apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT malinconicomario apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT cirillodonatella apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT pentimallifrancesca apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT ussaisilvia pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT petelinriccardo pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT giordanoantonio pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT malinconicomario pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT cirillodonatella pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients AT pentimallifrancesca pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients |